

AD _____

GRANT NUMBER DAMD17-96-1-6238

TITLE: Regulation of Growth Factor Release By Proteases
Inhibitors in Breast Cancer

PRINCIPAL INVESTIGATOR: Thomas H. Finlay, Ph.D.

CONTRACTING ORGANIZATION: New York University Medical Center
New York, New York 10016

REPORT DATE: September 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**Reproduced From
Best Available Copy**

DTIC QUALITY INSPECTED 4

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE September 1998	3. REPORT TYPE AND DATES COVERED Annual (15 Aug 97 - 14 Aug 98)	
4. TITLE AND SUBTITLE Regulation of Growth Factor Release By Proteases Inhibitors in Breast Cancer			5. FUNDING NUMBERS DAMD17-96-1-6238
6. AUTHOR(S) Thomas H. Finlay, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) New York University Medical Center New York, New York 10016			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES			19981210 115
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200) The aim of this proposal was to examine the role of proteases and protease inhibitors in the regulation of growth factor release in breast cancer. To this end we report the cloning, sequencing and properties of a TGF α -releasing protease present in breast ductal epithelium from an MCF-7 breast cancer cell cDNA library. The deduced 321 amino acid open reading frame shows a high degree of homology with the cell-surface serine proteases enteropeptidase, prekalikrein, hepsin and prostasin. Northern analysis, showed the presence of an approximately 4.2 kb mRNA species in total RNA from MCF-7 cells and normal breast ductal epithelial cells. A GST fusion protein, constructed from a portion of the PCR-7 open reading frame cDNA sequence, was used to raise antibodies in rabbits. On western blot analysis, the antibody recognized a 33 kDa polypeptide in MCF-7 cells under both reducing and non-reducing conditions. This antibody inhibited TPA-induced TGF α release from MCF-7 cells in a dose-dependent manner as compared to pre-immune sera. Immunohistochemistry of paraffin sections from normal and cancerous human breast tissue showed that the PCR-7 protein was restricted to the surface of ductal epithelial cells where it co-localized with the epidermal growth factor receptor.			
14. SUBJECT TERMS Breast Cancer Protease, protease inhibitor, Transforming growth factor- α , Epidermal growth factor-receptor.			15. NUMBER OF PAGES 20
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

9/10/98

Date

Table of Contents

Front Cover	1
SF 298 Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Materials and Methods	7
Results/Discussion	9
Conclusions	19
References	20

INTRODUCTION

The broad aim of this proposal is to test the hypothesis that the coordinate action of proteases and protease inhibitors are responsible for growth factor activation and release in the human breast cancer cell, and for the progression of breast cancer *in vivo*. One-third of all cases of advanced breast cancer are estrogen responsive, and recent epidemiological studies and studies using human breast cancer cells in culture strongly suggest a correlation between estrogens and the pathogenesis of breast cancer (Harris et al 1992). The mechanisms by which this occurs are not entirely clear. Certainly, estrogens have a direct effect on cell growth. In addition, they can stimulate the expression and release of a variety of polypeptide growth factors. It is highly likely that the tumorigenic effects of estrogens are due, at least in part, to the autocrine/paracrine action of these factors. Several of these polypeptides, including epidermal growth factor (EGF), and its analogs heregulin and transforming growth factor- α (TGF α) and the insulin-like growth factors (IGF-I and IGF-II), have been shown to require pericellular proteolysis for activation or release (Massagué and Pandiella 1993, Hooper et al 1997). To achieve homeostasis in a normal breast epithelial cell, levels of these pericellular growth factor activating proteases also must be regulated. We hypothesized that this was accomplished by the action of locally synthesized protease inhibitors. Thus an imbalance in the ratio between local levels of particular proteases and protease inhibitors could be responsible for increases in tumorigenic potential.

TGF α , a peptide structurally and functionally related to EGF, interacts with the EGF receptor (EGFR) and elicits a mitogenic response in a variety of cells (Lee et al 1995). TGF α expression occurs in normal breast tissue, breast tumors and breast cancer cells in culture and TGF α has been proposed to act as a major autocrine mediator of estrogen-stimulated growth in estrogen-dependent breast cancer cells (Harris et al 1992). Expression of the TGF α /EGFR pair have been shown to be associated with proliferation and angiogenesis in invasive breast cancer (De Jong et al 1998). TGF α is synthesized as part of a 20-22 kDa glycosylated, type I membrane protein precursor (proTGF α) which can be processed intracellularly and extracellularly by glycosylation and proteolysis to yield a family of polypeptides of from 6 to 17 Kda in size. (Massagué and Pandiella 1993, Baselga et al, 1996). Proteolytic processing occurs in two steps, the first results in cleavage between Ala³⁹ and Val⁴⁰ (Fig. 1). The second, occurring closer to the cell membrane, results in release of the 6 KDa mature TGF α peptide. While it is generally accepted that the second cleavage occurs between Ala⁸⁹ and Val⁹⁰, this does not rule out cleavage at another site (e.g between Lys⁹⁶ and Lys⁹⁷). Complete processing does not occur to the same extent in all tissues and it is certainly possible that shedding of TGF α from the cell surface may be accomplished by different proteases in different tissues (Hooper et al 1997, Arribas et al 1996). While all TGF α forms appear to possess some degree of biological activity, there is good evidence that particular biological actions may depend on the degree of proteolytic processing.




Figure 1. Cleavage sites in ProTGF α yielding mature 50 aa TGF α peptide. Arrows indicate the normal cleavage sites. Ala⁹⁹ begins the hydrophobic membrane-spanning region.

Results from this laboratory have clearly demonstrated a relationship between tumorigenicity of MCF-7 human breast cancer cells (as measured by growth in soft agar), endogenous synthesis of the protease inhibitor α_1 -antitrypsin (α_1 -AT) and release of TGF α (Tamir et al 1990, Finlay et al 1993a,b). Growth in soft agar was blocked by α_1 -AT whether added to the tissue culture media or synthesized by the tumor cell itself. A useful tool in these studies was a new MCF-7 cell subline, producing 10-fold higher levels of α_1 -AT than its parental cell line, constructed by stable transfection with an α_1 -AT cDNA (Yavelow et al 1997). Growth in soft agar and release of TGF α was decreased in cells transfected with

the α_1 -AT cDNA when compared to cells transfected with vector alone. Consistent with the above we had identified a serine protease with elastase-like activity, capable of forming a stable complex with α_1 -AT, on the MCF-7 cell surface.

Our specific aims as stated in our grant application were to:

1. To identify and clone the growth-modulating pericellular proteases from MCF-7 cells, particularly, the elastase-like enzyme(s) that are able to effect the release of TGF α from the tumor cell surface.
2. To show that the ability of MCF-7 sublines to form colonies in soft agar and tumors in nude mice is a function of their expression of α_1 -AT and specific pericellular proteases.
3. To extend our observations relating to TGF α release/activation made in MCF-7 human breast cancer cells in culture to other breast cancer cell lines, and to normal and malignant human breast tissue.
4. To test the hypothesis that the pericellular protease:protease inhibitor ratio responsible for TGF α release can be regulated by ST-3 and other potential effectors such as antiestrogens, phorbol esters and SEC receptor agonists. This information may provide insight into mechanisms by which protease and protease inhibitor levels may be independently controlled.

To accomplish the above specific aims, we proposed to carry out the sequence of studies described in our Statement of Work. While the project has not proceeded in exactly the order as originally anticipated, I believe that we are fairly well on track. Our progress is outlined below.

YEAR

STATUS OF PROJECTED STUDY

- | | |
|-----|---|
| 1-2 | Isolate, characterize and clone proteases from MCF-7 cells. This phase of the work has been completed and a manuscript describing the cloning and properties of the TGF α cleavage protease has been submitted for publication. |
| 1-3 | Compare production of protease and protease inhibitors by MCF-7 cell sublines with their ability to form colonies in soft agar and cause tumor formation in nude mice. Because of difficulties in generating the MCF-7 cell clones hyper-producing pro-TGF α , PCR-7 protease, and α_1 -antitrypsin-(Pittsburgh), this project is a little behind schedule. However, this phase of the work should be completed by the end of the year. |
| 1-3 | Extend our observations relating to TGF α release/activation made in MCF-7 human breast cancer cells in culture to other breast cancer cell lines, and to normal and malignant human breast tissue. We have demonstrated production of PCR-7 protease in normal and malignant breast epithelial tissue and anticipate looking at TGF α shedding in other breast cancer cell lines and in breast epithelial tissue over the next several months. Breast cancer cell studies using the non-transformed cell line MCF-10A, the ER-negative cell lines BT-20 and T47D and a second ER-positive cell line, ZR-65-1 are being carried out in collaboration with John Yavelow of Rider University. |
| 2-4 | Examine production and localization of proteases, protease inhibitors, growth factor receptors and sites of growth factor activation in normal and malignant breast tissue. In collaboration with Dr. Helen Feiner (Department of Anatomic Pathology) we have begun to look at histochemical localization of PCR-7 protease, EGF receptor and ProTGF α in normal and malignant breast tissue. |
| 1-4 | Test the hypothesis that the pericellular protease:protease inhibitor ratio responsible for TGF α release can be regulated by ST-3 and other potential effectors Identify potential modulators of protease inhibitor: protease ratio and growth factor activation/release in breast cancer cells and in ductal epithelium from human breast. |

METHODS AND MATERIALS

1. Construction of MCF-7 Cell Sublines Demonstrating Stable Over-expression of α_1 -Antitrypsin Pittsburgh (α_1 -ATp).

The α_1 -ATp mutant in the vector pMT3 was obtained from Dr. A. Rehemtulla of the University of Michigan Medical Center. The Eco RI-Sal I cDNA fragment was excised from the vector and blunt ended. After addition of HIND III linkers, the fragment was subcloned into the eukaryotic expression vector pRC/CMV (Invitrogen) which contains the gene encoding for neomycin resistance (neo^r). This is the same vector that was used to construct MCF-7 cell sublines over expressing α_1 -AT. The orientation of the insert with respect to the cytomegalovirus promoter was determined by restriction mapping of the subclones, and plasmid containing the insert in the sense orientation was amplified for transfection. Initially, MCF-7 cells were transfected by electroporation since this method was supposed to be more efficient. Although Northern analysis showed a slight increase in α_1 -ATp mRNA in some putative transfected colonies, none demonstrated an increase in secreted α_1 -ATp protein as measured by Western blotting. This might have been due to cells escaping selection because the plating density was too high. Subsequently we repeated the transfection using both the calcium phosphate method and the lipid transfection technique (LipoTAXI mammalian transfection kit, Stratagene). After transfection the cells were plated at low density and cultured for approximately 14 days in medium containing 550 μ g/ml Geneticin (G418). The media was changed every 4-5 days to remove dead cells. 21 distinct G418 resistant colonies were trypsinized using cloning rings and transferred to 15 mm wells. 10 of these colonies were selected for expansion and analysis. Two of the first seven colonies subjected to Northern analysis demonstrated elevated message levels indicating successful transfection (**Fig. 2A**). One clone (lane 2) over-expressed a much larger mRNA (approximately 4 Kb). Subsequently, the cells will be labeled with [³⁵S]-methionine and the media immunoprecipitated with antibody to α_1 -ATantitrypsin to determine expression of protein. Our finding that the PCR-7 protease (see below) may have an Arg/Lys specificity pocket adds considerable importance to the construction of this cell line as α_1 -ATp inhibits trypsin-like but not elastase-like enzymes while α_1 -AT inhibits both classes of proteases.

2. Construction of MCF-7 Cell Sublines Demonstrating Stable Over-expression of PCR-7 protease.

The cloning vector pSport 1 containing the PCR-7 protease cDNA was digested with Sal I. After filling in the ends with DNA polymerase 1 (Klenow) and ligating Hind III linkers the plasmid was digested with Hind III and Not I. This fragment was purified and ligated to the Hind III – Not I site of the eukaryotic expression vector pRC/CMV (see above). This strategy ensured that the insert is in the correct orientation for expression. MCF-7 cells were transfected with this construct by both the calcium phosphate and lipid transfection technique. The cells were treated as above and presently 10 clones are being amplified and analyzed. Three of the first six colonies subjected to Northern blot analysis demonstrated elevated message levels indicating successful transfection (**Fig. 2B**). With these cells both the media and cell lysates of metabolically labeled cells will be immunoprecipitated with antibody to PCR-7.

It should be noted that no significant difference in efficiency between the calcium phosphate and the lipid transfection method was observed. However, in the case of α_1 -Atp, the cells prepared by the lipid transfection technique were plated too heavily to permit selection of distinct colonies so all clones were selected from transfectants prepared by the calcium phosphate method. For the PCR-7 clones, transfectants prepared by both methods were selected.

3. Construction of MCF-7 Cell Sublines Demonstrating Stable Over-expression of proTGF α .

Because of the low endogenous expression of proTGF α and corresponding low levels of TGF α shedding in wild-type MCF-7 cells, obtaining reliable results in which TGF α release is used as an endpoint is difficult by standard assays. Even when using large numbers of cells (i.e. T-75 flasks), TGF α in the media must be concentrated either by ultra-filtration or immunoprecipitation prior to assay

either by ELISA or western blot analysis. To simplify routine assays we will construct an MCF-7 cell subline over expressing proTGF α . This will be accomplished using techniques similar to those used for the construction cell lines over expressing α_1 -AT, PCR-7 protease and α_1 -AT-(Pittsburgh). To this end we will subclone a 925 bp proTGF α cDNA (pHTGF1-10-925, ATCC) into the vector pRC/CMV. The Eco RI fragment will be blunt ended and after addition of HIND III linkers ligated into the expression vector. The orientation of the insert will be determined by restriction mapping.




Figure 2. Northern blot analysis of MCF-7 clones over-expressing α_1 -ATp and PCR-7 protease. Individual colonies were selected and expanded. Aliquots of expanded colonies were grown to confluence in wells of 6-well plates and total RNA was isolated with Genosys RNA Isolator. Approximately 8 μ g of total RNA from each sample was electrophoresed on 1.2% agarose gels, transferred to nylon membranes and hybridized with the appropriate 32 P-labeled cDNA probe. The bottom half of each figure shows a image of the ethidium bromide stained gel to estimate the degree of loading (A) α_1 -ATp. The probe used was a 405 bp PCR-generated fragment of the human α_1 -AT cDNA comprising nucleotides 234-639. Lane 8 contained 8 μ g of RNA from wild-type non-transfected MCF-7 cells. (B) PCR-7 Protease. The probe used to screen the blot was a 300 bp PCR-generated fragment of the full-length cDNA. Lane 7 contained 8 μ g of RNA from wild-type non-transfected MCF-7 cells. Neither of the probes recognized the message for antibiotic resistance coded for by the vector.

4. Effect of Protease Inhibitors on Growth of MCF-7 Cells in Soft Agar

Soft agar transformation assays of MCF-7 cells were carried out essentially as described previously (Tamir et al 1990). Cells, maintained for 24-48 hr. in RPMI-1640 media containing 10% charcoal-treated FBS, were plated in RPMI-1640 media containing 1% ultra low melting agarose (SeaPrep, FMC BioProducts), 10% charcoal-treated, TIC-depleted FBS, penicillin, streptomycin and glutamine with and without E2 (10^{-8} M) over a bottom layer of 2% of the same agarose. Cells were plated at a density of 10^4 cells per well in 30 mm tissue culture dishes and incubated at 37 C in an atmosphere containing 5% CO $_2$. After 14 days, the plates were stained for 24 hr. with 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyl tetrazolium chloride and the number of colonies per well (aggregates of more than 40 cells, >100 μ m) were counted manually.

In preliminary studies, cells were incubated with and without α_1 -AT (50 μ g/ml), the serine protease inhibitor 3,4 dichloroisocoumarin (DCI, 10^{-4} M) and the metalloprotease inhibitor BB-3103 (British Biotech, 10^{-4} M). As we had previously demonstrated, E2 stimulated colony formation. In addition, all three protease inhibitors significantly reduced colony formation by wild-type MCF-7 cells under these conditions. These, not particularly novel results, confirm that in our system both metallo- and seine proteases play a role in tumorigenesis.

RESULTS AND DISCUSSION

1. Cloning of the TGF α Releasing Enzyme

As we reported last year, degenerate oligonucleotides based on the conserved sequences about the his⁵⁷, asp¹⁰² and ser¹⁹⁵ residues in mammalian serine proteases were used to clone a potential TGF α -releasing serine protease from an MCF-7 breast cancer cell cDNA library. In the initial step, a series of approximately 500 bp fragments between the his⁵⁷ and ser¹⁹⁵ sites were amplified by PCR. The amplified sequences were then cloned into a PCR cloning vector, which was used to construct a mini-cDNA library. Clones from the mini library were selected by Southern blotting using a ³²P-labeled degenerate oligonucleotide probe based on the sequence about asp¹⁰². Several positive clones were sequenced. The 460 bp sequence of one strongly hybridizing clone, designated PCR-7, showed a high degree of homology to known serine proteases (64% identity in a 220 bp region at the 3' terminus to human trypsinogen-B and a 60% identity in a 120 bp region around the 5' terminus to human pancreatic protease). Northern blot analysis, using a PCR-7 cDNA probe, showed the presence of an approximately 4.2 kb mRNA species in total RNA from MCF-7 cells. Similar mRNA species were found in normal breast tissue, trophoblast, and proliferative phase uterine glandular epithelium but not in human U373MG glioma or HepG2 hepatoma cells.

Two cDNAs of approximately 3.8 and 3.2 kb containing the PCR-7 sequence were cloned from a second MCF-7 cell cDNA library using the PCR-7 sequence as a probe. Except for minor differences in the 3' sequence, the two clones appear to be identical where they overlap. Both clones hybridized to the same size mRNA as did the PCR-7 sequence used to screen the library. Last year we reported the sequence of approximately 2000 bp (plus an additional 500 bp at the 5' end) of the larger clone. We have now sequenced the entire 3271 bp cDNA at least twice and have resolved all apparent ambiguities (**Fig. 3**). The sequence has a 965 b open reading frame (bases 1766-2731) and an approximately 500 b 3' sequence containing the poly adenylation site. The deduced amino acid sequence from the open reading frame contains the His⁵⁷, asp¹⁰² and Ser¹⁹⁵ motifs characteristic of serine proteases (amino acid residues 119-124, 176-180 and 267-272 respectively) and is compatible with the S1 family of the SA clan of serine-type peptidases (Rawlings and Barrett, 1994). The PCR-7 protease may cleave peptide chains after Lys or Arg residues as it, like trypsin, hepsin and enterokinase contains an Asp²⁶⁶ at the base of the specificity pocket (S1 subsite) (**Fig. 4**). Elastase and chymotrypsin-like enzymes have cysteine and serine residues, respectively, at this site.

Using BLAST, a 45-55% identity at the amino acid level was found between the PCR-7 protease sequence and the serine proteases (or their zymogens) enterokinase precursor (Kitamoto et al 1995), hepsin (Leytus et al 1988), prekalikrein (Chung et al 1986), TMPRSS2 protease (Paolino-Giacobino, et al 1997), prostasin (Yu et al 1995) and drosophila protease stubble (Appel et al 1993) (**Table I**). Significantly, enterokinase precursor, hepsin, prekalikrein, and prostasin are all cell membrane-bound proteases. A high degree of homology was found at the nucleotide level with another cell surface protease, hepatocyte growth factor activator (Miyazawa et al 1993). The PCR-7 protease shows two potential membrane-anchoring N-myristoylation sites between deduced residues 43 and 54, three possible phosphorylation motifs at residues 6-9, 19-22 and 86-89 and a potential Asn glycosylation site at residues 238-241. These observations are consistent with the PCR-7 protease being a type II membrane protein. Enterokinase is activated by cleavage into disulfide-linked heavy and light chains by duodenase, a recently identified chymotrypsin-like serine protease (Sokolova et al 1998). A sequence very similar to the enterokinase cleavage site, ITPKIVGG, is present at residues 82-86 in the PCR-7 enzyme.

2. Production of Antibodies to the TGF α Cleavage Enzyme

The 460 bp PCR-7 cDNA was also ligated into the glutathione S-transferase (GST) gene fusion vector, pGEX-4T-1. This construct and the parental vector were used to transform *E. coli* and fusion protein expression was induced with IPTG. On SDS PAGE, 3 of 6 recombinant vectors displayed a prominent band of about 40 kDa representing the GST-PCR-7 fusion protein while the parental vector produced a prominent 29 kDa band characteristic of GST alone. Large scale cultures of bacteria containing the GST-PCR-7 fusion protein vector were prepared and substantial amounts of the GST-PCR-7 fusion protein was isolated. The fusion protein was used to raise antibodies in two rabbits. On western blot analysis, the antibody recognized a 33 kDa polypeptide in trophoblast and MCF-7 cells under both reducing and non-reducing conditions. This antibody inhibited TPA-induced TGF α release from MCF-7 cells in a dose-dependent manner as compared to pre-immune sera. Preliminary studies in last years report suggesting that this antibody is able to inhibit TPA-induced TGF α release from MCF-7 cells in a dose-dependent manner as compared to pre-immune sera were confirmed (**Fig. 5**).

MCF-7 cells were surface labeled with [³H]-diisopropylfluorophosphate (DIFP) and immunoprecipitated with antibody to the GST-PCR-7 fusion protein. When total proteins were analyzed by SDS-polyacrylamide gel electrophoresis two labeled bands of approximately 32 and 70 kDa respectively were detected. Pretreatment of the cells with O-tetradecanoyl-phorbol-13-acetate (TPA), which has previously been shown to stimulate the release of TGF α in MCF-7 cells in the presence of estradiol (Yavelow et al, 1997), had no apparent effect on the intensity of either band. Our failure to immunoprecipitate the ³H-DIFP labeled PCR-7 protease in this preliminary experiment is disturbing as it might indicate that the protein is not on the cell surface. However, it is likely that the labeled bands represent mixtures of several cell surface serine proteases of similar sizes, of which the PCR-7 protease is only a very small fraction.

Figure 3. Complete PCR-7 cDNA Sequence (3/98)

```

1      gagcgcccaaggagggcaccgcccgctggcgctggcgctggccctgcccggaaatccc
-----+-----+-----+-----+-----+-----+-----+
61     ctccgctcccgctcccgctggcgccgaccgcccggcaccgggacctagggg
-----+-----+-----+-----+-----+-----+-----+
121    gccgctgcccgcgcccgcgcccctgcggccatggagccggccgcccggcagggac
-----+-----+-----+-----+-----+-----+-----+
181    cggcgacgcgggcgcgggcggggagcccggtaccctcgccgcccggccgctccctg
-----+-----+-----+-----+-----+-----+-----+
241    gacgctgtgagaccgagcgccctcgggaccatgggtagcgtcgggcccgcgaag
-----+-----+-----+-----+-----+-----+-----+
301    ctgcggaactctggcgctcgcggagcccctggatcccccctagccccggggcttc
-----+-----+-----+-----+-----+-----+-----+
361    ggcggagggggcccgaaggactcggcggggactcaagtacaactcccggcaccgagaa
-----+-----+-----+-----+-----+-----+-----+
421    ccgctccccgggctctgaaagcccgccctgaattcatgttgaggccgctgctcttt
-----+-----+-----+-----+-----+-----+-----+
481    gtgaatggcttgaggaaaggcgtggagttcctgcccagtcacaacagtcagaaggaggaa
-----+-----+-----+-----+-----+-----+-----+
541    cacttaccgaacctctccgcaectcaaggacggtcagttgtgcagttctccacct
-----+-----+-----+-----+-----+-----+-----+
601    aagcatggcccggcgctgggtgctggtgcanccgctgactggccctctcttggct
-----+-----+-----+-----+-----+-----+-----+
661    ttctgaccggcccgcgaccacagaccgctngcagactagcggaggaagaaaccag
-----+-----+-----+-----+-----+-----+-----+
721    ttgctggggatcggcttcttggcttgcagttaccgggacgtgctgctccaga
-----+-----+-----+-----+-----+-----+-----+
781    aacgacctagccgaaggaaaccaacctgaaagcgtatggccctgcaacgacaggct
-----+-----+-----+-----+-----+-----+-----+
841    aggttcaatggctacatgaggatcaaaaatgagaatttggatgacctacagagaact
-----+-----+-----+-----+-----+-----+-----+
901    tccagaagtaccgatgactcctcctagtttactottaacaacacctacggatgctcttga
-----+-----+-----+-----+-----+-----+-----+
961    ccaactcactgagtttgaagcctggccagcaagtgaaaggacgctgaaagctgctgt
-----+-----+-----+-----+-----+-----+-----+
1021  ggtgaggtgactcaaacattcggaccgctcctcacttccctgcccgaactcgacgaca
-----+-----+-----+-----+-----+-----+-----+
1081  acagcgagtcctcctggccctaccacaaggagtcggctgtgacggccttcagcg
-----+-----+-----+-----+-----+-----+-----+
1141  tgcgctcaggggtaaggaccggggtggttctcagcccagacactgcccggagtcgc
-----+-----+-----+-----+-----+-----+-----+
1201  agggcagctcactgcctactactgctgagttcagatcccgcagacctggtggagg
-----+-----+-----+-----+-----+-----+-----+
1261  tcccgtcgcagtagcggatgataccagactcaagtcgtagggcctcgtggaaccctcc
-----+-----+-----+-----+-----+-----+-----+
1321  agggcagcgcgtcatggcggaggcgcgtagtcgctgcccccgggcgcgctccc
-----+-----+-----+-----+-----+-----+-----+
1381  tccggctcgcgactaccggctcctcgcgatcagtcagcagggggcgcccgcggg
-----+-----+-----+-----+-----+-----+-----+
1441  tgaagtcttgygtcacctcagtggtggttccccacggactccaaacagatcaga
-----+-----+-----+-----+-----+-----+-----+
1501  acttcaggaaacaccaaagtgaagtcaccaccgaaaggggtgcctgaggttttgtcatgtct
-----+-----+-----+-----+-----+-----+-----+
1561  agaacccaggaaacaacagctgcagcttggcctgcacgcccccgctgttgaaacttgaa
-----+-----+-----+-----+-----+-----+-----+
1621  tcttggctccttggttgcagctcgaaccggacgtggggggcgccacaaccttgaactt
-----+-----+-----+-----+-----+-----+-----+
1681  tgcgcttcaccagcccggctccctgacagcccctacccccctcatgcccgctgccagt
-----+-----+-----+-----+-----+-----+-----+
1741  acgcaagtggcgccgcaaggactgtcgggatggggcgagtacggcgacgggtca
-----+-----+-----+-----+-----+-----+-----+
1801  gggccctgcgggggaccccactcagtgtagcctgacctcccgacgtttgaccttg
-----+-----+-----+-----+-----+-----+-----+
1861  cccggagcctcccctggtgtagtcagctggactggaaggcgtgaaagcgtgaaactggaac
-----+-----+-----+-----+-----+-----+-----+
1921  cgtcctgagcagcggcgagcagcctggtgacggtgtaacaacaccttgagccccatgg
-----+-----+-----+-----+-----+-----+-----+
1981  geaggaagctgctcgcgcctgctggaccactgccaatgtgtggaactcggggtacc
-----+-----+-----+-----+-----+-----+-----+
2041  agccccacgcccctggtcagttgtgtagcctaccctccctctacacacctgaccttcc
-----+-----+-----+-----+-----+-----+-----+
2101  tcggggtcggggaccacgtcaacacccgtggatggaggaggatgttgactggaaggg
-----+-----+-----+-----+-----+-----+-----+
2161  actctcccagaacgctcctcactcactgataaccaacactgagcggcgcatcccg
-----+-----+-----+-----+-----+-----+-----+
2221  tgaggaggctctgcagacagtagtgcactatggttgcctcgcgcgcctagggc
-----+-----+-----+-----+-----+-----+-----+
2281  gctttgagggcaccctctctccagctgcctaggatgagcagctgfggagggccgcttacgta
-----+-----+-----+-----+-----+-----+-----+
2341  cgaacctcgggtggaagaggtcgacggatcctactcgtcgacacctcggcgaatgcact
-----+-----+-----+-----+-----+-----+-----+
2401  aagcccaggggacattcaacagcccctactcccagggcattaccaccaacattgact
-----+-----+-----+-----+-----+-----+-----+
2461  ttccgggtcccctgtaagtgtcggggtgatgggtccggtaatgggtggttgaactga
-----+-----+-----+-----+-----+-----+-----+
2521  gcacatgaaacattgaggtgcccaacaaccagcagatgtgaaaggtgcgcttcaaaatctcttt
-----+-----+-----+-----+-----+-----+-----+
2581  cgtgtaccttctaactccacgggtgtggtcgtacacctccacgcaagtttaagaaaa
-----+-----+-----+-----+-----+-----+-----+
2641  aacctgctggagcccggcgtgcctgcgggacacctgcccgaagatcagtgagagatcaacg
-----+-----+-----+-----+-----+-----+-----+
2701  ttggacgacctcgggcccgcacggagcccgtggacggggttccctatgcaacctctagtgc
-----+-----+-----+-----+-----+-----+-----+
2761  gggagaaatactcgggagaggtcccagttcctcgtcaccagaaacagcaacaagatca
-----+-----+-----+-----+-----+-----+-----+
2821  ccctcttatgacgctctcctccagggtcaagcagcagtggtcgttgcgttgcgttcttagt
-----+-----+-----+-----+-----+-----+-----+
2881  cagttcgttccactcagatcagtcctacaccgacacccggcttcttagtgaataacctnt
-----+-----+-----+-----+-----+-----+-----+
2941  gtcaagcgaaggtgagctcagtgagatgtggctgtggccgaaagatcgacttatggana
-----+-----+-----+-----+-----+-----+-----+
3001  cctacgactccagtaccctatgcccggggcagttcacgtgccgcacggggcggtgtatcc
-----+-----+-----+-----+-----+-----+-----+
3061  ggatgctgaggtcactgggtacggcccctcaagtgcacggcgtgcccccacatag
-----+-----+-----+-----+-----+-----+-----+
3121  ggaaaggagctgcgctgtgagctggccgactgcaccgaccacagcagctgagctcaact
-----+-----+-----+-----+-----+-----+-----+

```


2881	tagaaaacctctcgttccagcctccaaagtggagctggaggtgaggtgaggtgaggttctact -----+-----+-----+-----+-----+-----+-----+ atcttttgagcggaaggagtcgaggtttcacctcgaccctccatcttcccaagatga	3061	ggagcctctcagtgaaaggtggtgggctgcccggatctgggctgtgggccccttgggcca -----+-----+-----+-----+-----+-----+-----+ cctcggaggagtcactccaccacccccgacgcccctagaccgccacccccgggaaccccggt
2941	gacccaaactgggggcaaaagtttgaagacacagcttccccccgagcccccaagctgggcc -----+-----+-----+-----+-----+-----+-----+ ctgggttgacccccgttccaaacttctgtcgaagggcggtcggggttcgacccgg	3121	cgctcttgaggaaagcccaaggctcgggagaccctggaaaacagacgggtctcgagactgaaa -----+-----+-----+-----+-----+-----+-----+ gcgagaactccttcgggtccgagcctcctggacctttgtctgccagactctgacttt
3001	gaggcgctttgtgtatatctgcctccctgtctgtaaggagcagcgggaaacggagcttc -----+-----+-----+-----+-----+-----+-----+ ctccggcaaacacatatagacggaggggacagacattcctcgtcgccttgcctcgaag	3181	ttgtttaccagctcccaggtgggacttcagtggtgtattttgtgtaaatgagtaaaaca -----+-----+-----+-----+-----+-----+-----+ aacaaaaatggtcgaggtcccacctgaagtcacacacataaacacattactcattttgt
		3241	ttttatttncntttttaaaaaaaaaaaaaaa -----+-----+-----+-----+-----+-----+-----+ aaaaataaangaaaaatttttttttttttttt

Table I. Comparison of the Ser195 Catalytic Regions in PCR-7 and Related Serine Proteases

	266		272	
PCR-7 protease				GGVDSQCQGDSSGGPL
Enterokinase Human (p98073)				GGIDSCQGDSSGGPL
Hepsin Human (p05981)				GGIDACQGDSSGGPF
Trypsinogen 1 Human (p07477)				GGKDSQCQGDSSGGP
Chymotrypsinogen Bovine (p00766)				SGVSSCMGDSSGGPL
Elastase Human (p08218)				GVICTCNGDSSGGPL

GenBank accession numbers appear in brackets

Pcr-7	1	MGSASRKASSAMGRITVGVTSDEASCPKVNVTCTKHITYRCLNGLCTSKGNPECDKEDC
ENTEROKINASE	1	NWTTQISNDVCQLLGLGSGNSKPIFSTDDGGPFVKLNTAPDGHILITPSQOCLQDSLIRL
HEPSIN	1	~~~VAGLSCEEMGFLRALTHSELVDVRTAGANGTSGFFCVDEGRLPHTQRLLLEVISVCDPC
PROSTASIN	1	~~~~~MAQKGVLPGPQLGAVAILLYLGLLRSCTGAE
KALLIKREIN	1	GVNVCQETCTKMIRCOFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTOGSSCYSLR
STUBBLE	1	KTPTTTRPISSSSSSSSGIVTSSQRPTQPHRTPVLATSGIETNEISDSSIPDAGALGRV
consensus	1	
Pcr-7	61	SDGSDEKDCDCWLRSEFTRQARVVGGTDADEGEWPQVSLH....ALCGHICGASLISP
ENTEROKINASE	61	QCNHKSCGKKLAAQD..ITPKIVGGSNAKEGAWPWVVGLY...Y...GGRLICGASLVSS
HEPSIN	58	RGRFLAAICQDCGRKLEPVDRIVGGRTSLGRWPQVSLR...YDGA...HLCGGSLLSG
PROSTASIN	32	...GA..EAPCGVA..PQARITGSSAVAGQWPQVVSIT...YEGV...HVCGGSLVSE
KALLIKREIN	61	LCNTGD..NSVCTK..TSTRIVGGTNSSWGEPQVSLQ...VKLTAQRHLCCGSLIGH
STUBBLE	61	KTIISAARSECGVPTLARPETRIVGGKSAAFGRWPQVSVRRTSFFGFSSTHRCGGALINE
consensus	61	.. ** * *** * .. **..*
PCR-7	116	NWLVSAAHCYIDDRGFRYSIPTQDGLPGLARPEPAQRPVQERRLRKRIISHPFFNDFTFD
ENTEROKINASE	113	DWLVSAAHCVYGRNLEPSKWTAILGLHMKSN...LTSPQTVPRLIDEIVINPHYNRRRK
HEPSIN	112	DWVLTAAHCFPERNRVLSRWRVFAQAVAAQSPHGLQLGVAQVYHGGYLPFRDPNSENS
PROSTASIN	78	QWLVSAAHCFPSEHHK.EAYEVKLGCAHQLDS...YSEDAKVST.LKDIIPHESYLOEGSQ
KALLIKREIN	114	QWVLTAAHCFDGLPLQ.DVWRIYSGLINLSD...ITKDTPFSSQ.IKEIIPHONYKVSEGN
STUBBLE	121	NWVLTAAHCVDD..LLISQIRIRVGEYDFSHVQ...EQLPYIERGVAKKVVHPKYSFLTVE
consensus	121	..*..*..* * ..*
PCR-7	176	YDIALLELEKPAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYG..GALILQKGE
ENTEROKINASE	170	NDIAMMHLEFKVNYTDYIQPICLPEENOVFPGRNCSLAGWGTVVYQCT..TANILQEAD
HEPSIN	172	NDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGRICVTGWGHTQYQYQ..QAGVLQEAR
PROSTASIN	133	GDIALLOLSRPITFSRYIRPICLPAANASFPNGLHCTVTGWGHVAPSVLLTPKPLQOLE
KALLIKREIN	169	HDIALIKLQAPLNYTEFQKPICLPSKGDSTIYTNCWVTGWGFSKEKCEI..QNILQKVN
STUBBLE	177	YDLALVKLEOPLEFAPHVSPICLPETDSSL.IGMNATVTGWGRLSEGCTL..PSVLEVS
consensus	181	*..*..* ..*..* ..*..* ..*
PCR-7	234	IRVINQTTCEENLL.....PQOITPRMVCVEFLSGGVDSQCQDSCGGPIS...SVEADG
ENTEROKINASE	228	VPLLSNERCQ.....QOMPEYNTTENMICAGYEEGGIDSCQDSCGGPIMCQEN...N
HEPSIN	230	VPIISNDVCGNADFYGNQ.....IKPKMFCAGYPEGGIDACQDSCGGPFVCEDSISRTP
PROSTASIN	193	VPLISRETNCCLYNIDAKPEEPHFVQEDMVCAGYVEGGKACQDSCGGPISCPVE...G
KALLIKREIN	227	HPLVTNEECQKRY.....QDYKITORMVCAGYKEGGKDAKGDSCGGPIVCKHN...G
STUBBLE	234	VPIVSNDCNCKSMFMRAGRQE...FIPDIFLCAGYETGGQDSCQDSCGGPIQAK...SQDG
consensus	241	... * ..*..*..*..*..*..*..*..*..*
PCR-7	283	RIFQAGVSWGDGCAQRNKPGVYTRLPLERDWDIKENTGV~~~~~
ENTEROKINASE	277	RWELAGVTSFGYKCALPNRPGVYARVSRFTEWIQSFLH~~~~~
HEPSIN	284	RWRLCGIVSWGTCALAQKPGVYTKVSDREWFQAIKTHSEASGMVTQL
PROSTASIN	249	LWYLTGIVSWGDAAGARNRPGVYTLASSYASWIQSKVTELQPRVVPQT~~
KALLIKREIN	276	MWRLVGIITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMOSPA
STUBBLE	288	RFFLAGIISWIGICAEANLPGVCTRISKETPWILEHVR~~~~~
consensus	301	*..*..* ..*..* ..*..* ..*

Figure 4. Consensus Sequence of PCR-7 and Related Serine Proteases




Figure 5. Antibody to PCR-7 fusion protein blocks release of TGF α from MCF-7 cells. MCF-7 (ML) cells were maintained in phenol red - free DMEM containing 10% FBS. Estradiol (10^{-8} M) was added for 24 hours. Cells were then washed twice with serum-free media and allowed to condition serum-free DMEM containing estradiol and IgG for 30 min. TPA (50 ng/ml) was added and the cells were incubated for an additional 4 hours. Conditioned media were concentrated on C₁₈ SEP-columns equilibrated with 10% acetonitrile-0.1% TFA eluting with 40% acetonitrile-0.1% TFA. Samples were taken to dryness and resuspended in PBS. TGF α levels were determined using a TGF α ELISA assay (Oncogene Science) according to the manufacturer's

instructions. Results are reported as the percentage of TGF α released in the presence of antibody (IgG) to the PCR-7-GST fusion protein as compared to the same level of pre-immune IgG.

3. PCR-7 Protein is Conserved in Mammalian Species.

Southern analysis, using a PCR-7 cDNA probe, indicated the presence of homologous sequences in human, mouse, baboon, rat and rabbit but not in chicken or drosophila genomic DNA (Fig. 6). Using this same probe, expression of an mRNA specie similar in size to that found in MCF-7 cells, human breast and uterine epithelium and in trophoblast was demonstrated in mouse testes, kidney, ovary and uterus (Fig. 7). RNA from mouse breast or placenta was not tested.




Figure 6. Southern Blot Analysis for Related PCR-7 Protein Genes in Genomic DNA from Various Species. Genomic DNA (15 μ g) isolated from the species indicated, was digested with either Pst1 or EcoR1 and electrophoresed on a 0.8% agarose gels. After alkaline denaturation and neutralization, the DNA was transferred to GeneScreen nylon membrane, fixed by baking and hybridized with a ³²P-labeled PCR-7 probe.





Figure 7. Northern Blot Analysis of mRNA From Various Mouse Tissues. The blot was screened with a ^{32}P -labeled 300 bp fragment of the full-length PCR-7 protease cDNA generated by PCR.

4. Immunohistochemical Localization of PCR-7 Protein in MCF-7 Cells and Normal and Malignant Breast Tissue

IgG from PCR-7 antisera was purified by ammonium sulfate precipitation followed by ion-exchange chromatography on DEAE-cellulose. Using this IgG fraction, the PCR-7 protein was immunohistochemically localized to the cell surface of formalin-fixed MCF-7 cells (Fig. 8). We



have begun to examine paraffin sections of tissues from reduction mammoplasty and malignant and adjacent 'normal' breast tissue histologically for the presence of EGFR, proTGF α , α_1 -AT and the PCR-7 protease. These studies are being carried out with the cooperation of Helen Feiner, M.D. of the Department of Pathology, who has provided us with the samples and who has assisted us with the histology. In preliminary studies we have examined tissues from both normal regions and severe cancers. Once we have documented the differences between normal tissue and severe cancers, we will look at intermediate forms such as carcinoma *in situ*. Consistent with our findings in MCF-7 cells, PCR-7 co-localized with EGFR to the surfaces of breast epithelial cells (Fig. 9). In a highly malignant breast cancer (Fig. 10), staining for PCR-7 appeared to be reduced, a not uncommon occurrence when normal control mechanisms are lost.

Figure 8. Immunohistochemical localization of the PCR-7 protease to the surface of MCF-7 cells (left). MCF-7 cells were cultured in plastic chamber slides to confluency. After 2 PBS washes, cells were fixed with 4 % para-formaldehyde and rehydrated. Endogenous peroxidase was quenched for 5 min using 5 % hydrogen peroxide in 100 % methanol. After 2 PBS washes, slides were incubated overnight at 4 C using

115 $\mu\text{g/ml}$ of rabbit polyclonal anti-PCR7 antibody or the same amount of pre-immune IgG. Treatment with antirabbit peroxidase conjugate and color development with diaminobenzidine were carried out using the Vectastain ABC kit. Samples were counterstained with hematoxylin.




Figure 9. Immunohistochemical co-localization of PCR-7 protease and EGFR to outer surfaces of breast epithelial cells. Five μ M paraffin-embedded tissue sections from a normal region of a benign breast tumor were applied to poly-L-lysine treated glass slides and deparaffinized for 2 h at 60 C before xylene and ethanol rehydration. Endogenous peroxidase was quenched for 5 min using 5 % hydrogen peroxide in 100 % methanol. After 2 PBS washes slides were incubated overnight at 4 C using 115 μ g/ml of rabbit polyclonal anti-PCR7 antibody, the same amount of pre-immune IgG or 2 μ g/ml of mouse monoclonal anti-human EGF-R antibody. Treatment with antirabbit or antimouse peroxidase conjugate and color development with diaminobenzidine were carried out using the Vectastain ABC kit. Samples were counterstained with hematoxylin and one set of tissues was stained with hematoxylin and eosin for morphology.




Figure 10. Immunohistochemical localization of PCR-7 protease in malignant breast carcinoma (8031). Five μM paraffin-embedded tissue sections were applied to poly-L-lysine treated glass slides and deparaffinized for 2 h at 60 C before xylene and ethanol rehydration. Endogenous peroxidase was quenched for 5 min using 5 % hydrogen peroxide in 100 % methanol. After 2 PBS washes, the slides were incubated overnight at 4 C using 115 $\mu\text{g}/\text{ml}$ of rabbit polyclonal anti-PCR7 antibody. Treatment with antirabbit peroxidase conjugate and color development with diaminobenzidine were carried out using the Vectastain ABC kit. Samples were counterstained with hematoxylin and one set of tissues was stained with hematoxylin and eosin for morphology.

CONCLUSIONS

Degenerate oligonucleotides based on the conserved sequences about the his⁵⁷ and ser¹⁹⁵ residues in mammalian serine proteases were used to clone a novel 3270 bp sequence (PCR-7) from an MCF-7 breast cancer cell cDNA library. The deduced 321 amino acid open reading frame shows a high degree of homology with the cell-surface serine proteases enteropeptidase, prekalikrein, hepsin and prostasin. Southern analysis, using a PCR-7 cDNA probe, indicated the presence of homologous sequences in monkey, mouse, and rabbit but not in chicken or drosophila DNA. Northern analysis, using this same probe, showed the presence of an approximately 4.2 kb mRNA species in total RNA from MCF-7 cells, normal breast ductal epithelial cells, trophoblast, and uterine glandular epithelium but not in human U373MG glioma or HepG2 hepatoma cells. Using this probe, expression of a similar-sized mRNA was demonstrated in mouse testes, kidney, ovary and uterus. In MCF-7 cells, expression of the PCR-7 mRNA was not significantly stimulated by estradiol or TGF α , but was stimulated by IL-6 (200%) and IL-1 (300%). A GST fusion protein, constructed from a portion of the PCR-7 open reading frame cDNA sequence, was used to raise antibodies in rabbits. On western blot analysis, the antibody (IgG fraction) recognized a 33 kDa polypeptide in trophoblast and MCF-7 cells under both reducing and non-reducing conditions. This antibody inhibited TPA-induced TGF α release from MCF-7 cells in a dose-dependent manner as compared to pre-immune sera and blocked MCF-7 cell proliferation as measured by [³H]-thymidine incorporation. Immunohistochemistry of paraffin sections from normal human breast tissue showed that the PCR-7 protein was restricted to the surface of ductal epithelial cells where it co-localized with the epidermal growth factor receptor.

REFERENCES

- Appel, L.F., Prout, M., Abu-Shumays, R., Hammonds, A., Garbe, J.C., Fristrom, D.K. and Fristrom, J.W. 1993 Proc Natl Acad Sci USA 90:4937-4941.
- Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S. and Massagué, J. 1996 Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 271: 11376-11382.
- Baselga, J., Mendelsohn, J., Kim, Y-M. and Pandiella, A. 1996 Autocrine regulation of membrane transforming growth factor- α cleavage. J Biol Chem 271:3279-3284.
- Chung, D.W., Fujikawa, K., McMullen, B.A. and Davie, E.W. (1986) Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25: 2410-2417.
- De Jong, J.S., Van Diest, P.J., Van der Valk, P. and Baak, J.P. 1998 Expression of growth factors, growth inhibiting factors and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 184:53-57.
- Finlay, T.H., Tamir, S., Kadner, S.S., Yavelow, J. and Levitz, M. 1993a α_1 -Antitrypsin and Anchorage-Independent Growth of MCF-7 Breast Cancer Cells. Endocrinology 133:996-1002.
- Finlay, T.H., Kadner, S.S. and Tamir, S. 1993b Protease Inhibitor Synthesis by MCF-7 Breast Cancer Cells. *in* Protease Inhibitors as Cancer Chemopreventative Agents. (W. Troll and A. Kennedy, Eds.). Plenum Press, New York. pp 141-159.
- Harris, J.R., Lippman, M.E., Veronesi, U.V., Willett, W. 1992 Breast Cancer N. Engl J Med 327:319-328, 390-398, 473-480.
- Hooper, N.M., Karran, E.H. and Turner A.J. 1997 Membrane protein secretases. Biochem J 321:265-279.
- Kitamoto, Y., Veile, R.A., Donis-Keller, H. and Sadler, J.E. 1995 cDNA sequence and chromosomal localization of human enterokinase the proteolytic activator of trypsinogen. Biochemistry 34: 4562-4568.
- Lee, D.C., Fenton, S.E., Berkowitz, E.A. and Hissong, M.A. 1995 Transforming Growth Factor α : Expression, Regulation, and Biological Activities. Pharm. Rev. 47:51-85.
- Leytus, S.P., Loeb, K.R., Hagen, F.S., Kurachi, K., Davie, E.W. (1988) A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry. 27:1067-1074.
- Massagué, J. and Pandiella, A. 1993 Membrane-Anchored Growth Factors. Ann Rev Biochem 62:515-541.
- Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y. and Kitamura, N. (1993) Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem. 268:10024-10028.
- Paolino-Giacobino, A., Chen, H., Peitsch, M.C., Rossier, C. and Antronarakis, S.C. 1997 Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3 Genomics 44:309-320.
- Rawlings ND, Barrett AJ 1994 Families of serine peptidases. Meth Enzymol 244:19-61
- Sokolova, E.A., Starkova, N.N., Vorotyneva, T.I. and Zamolodchikova, T.S. 1998 A serine protease from the bovine duodenal mucosa, chymotrypsin-like duodenase. Eur J Biochem 255:501-507.
- Tamir, S., Kadner, S.S., Katz, J. and Finlay, T.H. 1990 Regulation of Antitrypsin and Antichymotrypsin Synthesis by MCF-7 Breast Cancer Cell Lines. Endocrinology 127:1319-1328.
- Yavelow J, Tuccillo A, Kadner SS, Katz J, Finlay TH. 1997 α_1 -Antitrypsin Blocks Release of TGF α from MCF-7 Human Breast Cancer Cells. J. Clin. Endo. Metabol 82:745-752.
- Yu, J.X., Chao, L. and Chao, J. 1995 Molecular Cloning, tissue-specific expression and cellular localization of human prostaticin mRNA. J. Biol. Chem 270:13483-13489.